• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体内注射贝伐单抗后的眼内炎:巴基斯坦三级医疗中心的发病率、管理及视力转归

Endophthalmitis Postintravitreal Bevacizumab Injections: Incidence, Management, and Visual Outcome in Tertiary Care Center in Pakistan.

作者信息

Rizwan Amna, Asghar Asfandyar, Sughra Ume, Yasmin Naila

机构信息

Department of Ophthalmology, KEMU, Lahore, Pakistan.

Department of Ophthalmology, Fauji Foundation Hospital, Rawalpindi, Pakistan.

出版信息

Oman J Ophthalmol. 2022 Mar 2;15(1):20-24. doi: 10.4103/ojo.ojo_103_21. eCollection 2022 Jan-Apr.

DOI:10.4103/ojo.ojo_103_21
PMID:35388253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8979382/
Abstract

PURPOSE

The purpose is to study the incidence, characteristics, management, and visual outcome of endophthalmitis postintravitreal bevacizumab (Avastin®) injections.

METHODS

Retrospective cohort study conducted at Fauji Foundation Hospital that is a tertiary care center in Rawalpindi, Pakistan. The study duration was from January 1, 2015 to March 31, 2020. A total of 2321 eyes of 1407 patients were treated with Intravitreal bevacizumab (IVB) in a minor operation theater using standard aseptic measures. We studied the incidence, clinical characteristics, treatment, and visual outcomes of endophthalmitis post-IVB.

RESULTS

Seven eyes (0.30%) out of 2321 eyes developed post-IVB endophthalmitis during the study period. Three eyes (42.8%) were culture positive and four eyes (57.2%) were culture negative. Five eyes (71.4%) showed visual improvement and two eyes (28.6%) did not show visual improvement.

CONCLUSION

Prompt intravitreal antibiotic along with vitreous tap in cases of postintravitreal endophthalmitis may prevent vision loss which provides a useful alternative to immediate pars plana vitrectomy that requires more expertise, equipment, and an operation theater.

摘要

目的

研究玻璃体内注射贝伐单抗(阿瓦斯汀®)后眼内炎的发生率、特征、处理方法及视力预后。

方法

在巴基斯坦拉瓦尔品第的三级医疗中心法吉基金会医院进行回顾性队列研究。研究时间为2015年1月1日至2020年3月31日。共有1407例患者的2321只眼在小型手术室采用标准无菌措施接受了玻璃体内贝伐单抗(IVB)治疗。我们研究了IVB后眼内炎的发生率、临床特征、治疗方法及视力预后。

结果

在研究期间,2321只眼中有7只眼(0.30%)发生了IVB后眼内炎。3只眼(42.8%)培养阳性,4只眼(57.2%)培养阴性。5只眼(71.4%)视力改善,2只眼(28.6%)视力未改善。

结论

对于玻璃体内注射后眼内炎病例,及时进行玻璃体内注射抗生素并抽取玻璃体,可能预防视力丧失,这为立即进行需要更多专业知识、设备和手术室的玻璃体切割术提供了一种有用的替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d941/8979382/23f39ee5a56b/OJO-15-20-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d941/8979382/f0bffc7b6a27/OJO-15-20-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d941/8979382/23f39ee5a56b/OJO-15-20-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d941/8979382/f0bffc7b6a27/OJO-15-20-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d941/8979382/23f39ee5a56b/OJO-15-20-g002.jpg

相似文献

1
Endophthalmitis Postintravitreal Bevacizumab Injections: Incidence, Management, and Visual Outcome in Tertiary Care Center in Pakistan.玻璃体内注射贝伐单抗后的眼内炎:巴基斯坦三级医疗中心的发病率、管理及视力转归
Oman J Ophthalmol. 2022 Mar 2;15(1):20-24. doi: 10.4103/ojo.ojo_103_21. eCollection 2022 Jan-Apr.
2
Incidence and management of acute endophthalmitis after intravitreal injection of bevacizumab.玻璃体内注射贝伐单抗后急性眼内炎的发生率与处理。
Int Ophthalmol. 2022 Jun;42(6):1827-1833. doi: 10.1007/s10792-021-02180-7. Epub 2022 Jan 26.
3
Klebsiella Cluster Endophthalmitis following Intravitreal Bevacizumab: Role of Early Detection, Pars Plana Vitrectomy, and Intracameral Moxifloxacin.眼内注射贝伐单抗后发生克雷伯氏菌属簇生菌眼内炎:早期发现、经平坦部玻璃体切除术和前房内莫西沙星的作用。
Ocul Immunol Inflamm. 2022 Jan 2;30(1):11-15. doi: 10.1080/09273948.2020.1808229. Epub 2020 Sep 23.
4
Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection.玻璃体内注射贝伐单抗(阿瓦斯汀)后急性眼内炎的发生率和处理。
Eye (Lond). 2009 Dec;23(12):2187-93. doi: 10.1038/eye.2009.7.
5
Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.玻璃体培养指导下内眼注药后眼内炎治疗策略的改变
Am J Ophthalmol. 2019 Nov;207:224-231. doi: 10.1016/j.ajo.2019.06.008. Epub 2019 Jun 13.
6
Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.单一转诊中心玻璃体内注射抗血管内皮生长因子后急性眼内炎的发病率及视力预后
Int Ophthalmol. 2023 Mar;43(3):867-876. doi: 10.1007/s10792-022-02489-x. Epub 2022 Sep 14.
7
Incidence of Acute Endophthalmitis After Intravitreal Bevacizumab Injection at a Tertiary Care Hospital in Lahore.拉合尔一家三级护理医院玻璃体内注射贝伐单抗后急性眼内炎的发生率
Cureus. 2021 Feb 6;13(2):e13185. doi: 10.7759/cureus.13185.
8
Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.在科威特两个手术室现场制备分装样本后玻璃体内注射贝伐单抗引发眼内炎的发生率
Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):64-70. doi: 10.4103/0974-9233.171784.
9
Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series.与玻璃体内注射贝伐单抗相关的无菌性眼内炎患者的临床特征、处理方法和转归:回顾性病例系列研究。
Int Ophthalmol. 2024 May 5;44(1):216. doi: 10.1007/s10792-024-03134-5.
10
Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.眼内抗血管内皮生长因子注射后眼内炎的临床特征。
Retina. 2010 Jul-Aug;30(7):1051-7. doi: 10.1097/IAE.0b013e3181cd47ed.

引用本文的文献

1
Off-label use of Avastin in Pakistan: Lessons from the 2023 Punjab outbreak.阿瓦斯汀在巴基斯坦的超说明书用药:2023年旁遮普邦疫情的教训
J Public Health Res. 2025 Jul 29;14(3):22799036251361620. doi: 10.1177/22799036251361620. eCollection 2025 Jul.

本文引用的文献

1
Long-term visual outcomes of endophthalmitis and the role of systemic steroids in addition to intravitreal dexamethasone.眼内炎的长期视力结果以及在玻璃体内注射地塞米松之外使用全身皮质类固醇的作用。
BMC Ophthalmol. 2020 May 6;20(1):181. doi: 10.1186/s12886-020-01449-2.
2
Vitrectomy for endophthalmitis: 5-year study of outcomes and complications.玻璃体切除术治疗眼内炎:5年疗效与并发症研究
BMJ Open Ophthalmol. 2020 Mar 24;5(1):e000423. doi: 10.1136/bmjophth-2019-000423. eCollection 2020.
3
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach.
玻璃体内注射血管内皮生长因子抑制剂:实用方法
Ophthalmol Ther. 2020 Mar;9(1):191-203. doi: 10.1007/s40123-020-00230-4. Epub 2020 Feb 7.
4
Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.玻璃体内注射后眼内炎的预测因素:基于注射方案和聚维酮碘浓度的多变量分析
Ophthalmol Retina. 2019 Jan;3(1):3-7. doi: 10.1016/j.oret.2018.09.013. Epub 2018 Sep 25.
5
Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents.玻璃体内注射抗血管内皮生长因子药物后眼内炎的致病病原体
Rambam Maimonides Med J. 2018 Sep 2;9(4):1-6. doi: 10.5041/RMMJ.10348.
6
Current Evidence for the Prevention of Endophthalmitis in Anti-VEGF Intravitreal Injections.抗血管内皮生长因子玻璃体内注射预防眼内炎的当前证据
J Ophthalmol. 2018 Jul 24;2018:8567912. doi: 10.1155/2018/8567912. eCollection 2018.
7
Incidence of endophthalmitis after intravitreal injections at a tertiary care hospital.三级医院玻璃体腔内注射后眼内炎的发生率。
Can J Ophthalmol. 2018 Apr;53(2):94-97. doi: 10.1016/j.jcjo.2017.07.027. Epub 2018 Mar 9.
8
Incidence of Endophthalmitis after Intravitreal Injections: Risk Factors, Microbiology Profile, and Clinical Outcomes.眼内注射后眼内炎的发生率:危险因素、微生物特征和临床结局。
Ocul Immunol Inflamm. 2018;26(4):559-568. doi: 10.1080/09273948.2018.1430238. Epub 2018 Feb 13.
9
Incidence of acute endophthalmitis after office based intravitreal bevacizumab injection.门诊玻璃体腔内注射贝伐单抗后急性眼内炎的发生率。
J Pak Med Assoc. 2017 Dec;67(12):1917-1919.
10
Predictors of visual outcome and the role of early vitrectomy in streptococcal endophthalmitis.链球菌性眼内炎的视力预后预测因素和早期玻璃体切除术的作用。
Clin Exp Ophthalmol. 2018 May;46(4):424-431. doi: 10.1111/ceo.13077. Epub 2017 Nov 2.